-
Nystatin (Fungicidin) in Translational Assays
2026-08-28
Nystatin (Fungicidin) combines ergosterol-targeted membrane disruption with practical utility in Candida, mycoplasma, adhesion, resistance, and formulation studies. This guide shows how to build reproducible antifungal assays and how nanoparticle-uptake findings can inform—but not substitute for—future delivery experiments.
-
Oteseconazole (VT-1161) Assay Workflows
2026-08-28
Build more informative Candida susceptibility studies with Oteseconazole (VT-1161), a selective fungal CYP51 inhibitor suited to species panels, resistance profiling, and mechanism-linked validation. This guide combines practical dilution workflows with transporter-aware interpretation for translational antifungal research.
-
Hepatic sEH, Nrf2, and Osteoclastogenesis in Osteoporosis
2026-08-27
A recent Free Radical Biology and Medicine study identifies a liver–bone signaling axis in which hepatic soluble epoxide hydrolase alters circulating 14,15-EET and 14,15-DHET, suppressing Nrf2 activity and promoting osteoclastogenesis. By combining patient samples, an ovariectomy-induced mouse model, liver-specific knockdown, pharmacological inhibition, and transcriptomics, the study connects epoxyeicosatrienoic acids metabolism with redox imbalance and bone loss.
-
1-Phenyl-2-Pentanol and Liver Fibrosis
2026-08-27
The reference study identifies 1-phenyl-2-pentanol from Moringa oleifera leaves as an inhibitor of profibrotic activation in TGF-β1-stimulated LX-2 hepatic stellate cells. By combining fibrosis-marker analysis with proteomics and molecular docking, the work connects reduced extracellular-matrix signaling with possible modulation of the Wnt/β-catenin pathway while highlighting the need for in vivo validation.
-
JAK Inhibitors and Endothelial Cardiovascular Risk
2026-08-26
A 2025 ACR Open Rheumatology study compared six JAK inhibitors in cytokine-stimulated human endothelial cells, separating anti-inflammatory effects from changes linked to adhesion, coagulation, and cell death. The results show that reducing IL-6 does not necessarily normalize endothelial thrombo-inflammatory or viability pathways, highlighting the limits of treating JAK inhibitors as a uniform class.
-
Griseofulvin Workflows for Microtubule Assays
2026-08-26
Build reproducible fungal mitosis, microtubule dynamics, and aneugenicity experiments with Griseofulvin. This guide combines solvent handling, time-course design, mechanistic controls, and troubleshooting for research teams moving from phenotype to pathway-level evidence.
-
Colistin–Gamithromycin Synergy in P. multocida
2026-08-25
This study evaluated colistin–gamithromycin combinations against Pasteurella multocida using susceptibility testing, time-kill experiments, pharmacokinetics, and a neutropenic murine pneumonia model. Its main contribution is showing that synergy was strongest in isolates with higher colistin MICs, while PK/PD analysis supported substantially lower gamithromycin exposure during combination therapy.
-
RSL3: A GPX4 Inhibitor for Ferroptosis Assays
2026-08-25
Explore how RSL3, a glutathione peroxidase 4 inhibitor, converts redox vulnerability into a rigorously testable ferroptosis phenotype. This article connects GPX4 perturbation with TEAD2 biology, RAS-driven models, and evidence-based assay design.
-
Fenofibrate Workflows for PPARα-YAP Research
2026-08-24
Build reproducible Fenofibrate assays around PPARα engagement, lipid metabolism, and downstream YAP signaling rather than relying on viability readouts alone. This guide connects stock preparation, time-resolved cell workflows, liver enlargement models, and cancer assays with practical troubleshooting for stronger mechanistic interpretation.
-
Ibrexafungerp (MK 3118): Evidence & Workflows
2026-08-24
Ibrexafungerp, also known as MK 3118 or SCY-078, is an oral triterpenoid glucan synthase inhibitor with activity against several resistant Candida phenotypes. Clinical approval covers vulvovaginal candidiasis and reduction of recurrent vulvovaginal candidiasis, while invasive candidiasis remains an investigational application.
-
Graphene FIR and Apoptosis in Melanoma
2026-08-23
The reference study shows that graphene-mediated far-infrared radiation suppresses malignant melanoma through coordinated apoptosis induction, G0/G1 cell-cycle arrest, altered hypoxia-associated signaling, and tumor-growth inhibition. Caspase-inhibitor rescue experiments further implicate caspase-9 and caspase-3 as functional components of the response, providing a rationale for pathway-focused follow-up studies.
-
Mithramycin A: From G-C DNA to Translational Insight
2026-08-22
A thought-leadership guide to using Mithramycin A as a mechanistic transcriptional probe, linking G-C-rich DNA binding and c-myc biology with the miR-24-3p/Sp1/PI3K findings in doxorubicin-induced cardiac injury.
-
Captopril Workflows for ACE and Bradykinin Research
2026-08-22
Captopril provides a practical way to connect ACE inhibition in hypertension research with functional studies of bradykinin-dependent intestinal motility. This guide translates its biochemical profile into reproducible enzyme, organ-bath, and oncology workflows, with controls that help separate upstream ACE effects from direct receptor signaling.
-
Z-VAD-FMK Workflow for Apoptosis Research
2026-08-21
Z-VAD-FMK provides a practical causal test for caspase-dependent cell death, from APL models to immune-cell assays. This workflow combines inhibitor timing, orthogonal apoptosis readouts, and stock-handling controls to distinguish true apoptosis inhibition from assay artifacts.
-
Exogenous NADH Potentiates Aminoglycosides in E. tarda
2026-08-20
The 2024 Virulence study shows that exogenous NADH can reprogram Edwardsiella tarda metabolism, increase ATP availability, and strengthen neomycin-mediated bacterial killing. Its broader contribution is a metabolism-based antibiotic-potentiation strategy that was also examined with other antibiotic classes and resistant bacterial models.